Brief: Adaptimmune Therapeutics Reports Q1 Results

Adaptimmune Therapeutics

12/05/2023 14:26

May 12 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * QTRLY EARNINGS PER SHARE     $ 0.00
    * REVENUE FOR Q1 ENDED MARCH 31, 2023 WAS $47.6 MILLION,
VERSUS
$3.6 MILLION FOR SAME PERIOD IN 2022
    * Q1 EARNINGS PER SHARE VIEW $-0.15, REVENUE VIEW $4.9
MILLION --
REFINITIV IBES DATA
    * ESTIMATE CASH RUNWAY OF COMBINED COMPANY, POST MERGER WITH
 TCR²
THERAPEUTICS INC, WILL EXTEND INTO EARLY 2026

Source: (https://shorturl.at/vxHX4)
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))